The race to uncover the next 10-baggers is on now that markets seem to be well along in the process of signaling to investors that the new bull has been born.
Evidence is all around: investor sentiment has rebounded from deep pessimism to sudden optimism on stocks. A Reuters poll this week of analysts finds that all 106 expect the Fed to hike by 25bps at next week’s meeting, taking the Fed Funds benchmark overnight interest rate to the 5.25%-5.50% range. But only 19 of them think the Fed will hike any more after that. And yet, there are no signs—even on the distant horizon—of recession risk.
Meanwhile, new bull market themes are arising, and a new paradigm of growth is emerging. With so much cash on the sidelines, the stage is set for some potentially rewarding action for small-cap growth investors able to spot new darlings in the making.
One such potential “darling in the making” on the Nasdaq is still trading under $2/share but with growing sales and a growing brand footprint in an explosive growth market: Mangoceuticals, Inc. (NASDAQ: MGRX).
We have profiled the name before. But news this week suggests the potential for a faster path toward blossoming into high visibility as a growth play than we had been expecting.
Disrupting a $31 Billion Market
MGRX management has started to demonstrate a unique skill for marketing and messaging. The company operates in the the men’s health and wellness space, which is worth over $30 billion worldwide and is growing at a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors.
In that space, there hasn’t been a whole lot of impressive work done on the marketing side. MGRX aims to change that.
This factor has two faces.
First, the company has done a terrific job of finding a potentially disruptive messaging tone. Its flagship product is Mango, and ED treatment that combines a selection of compounds to target the challenges men face in intimate situations, crafted with FDA-approved ingredients. It now has both tadalafil and sildenafil versions.
The messaging around these products is designed to leverage humor and an open and confident framing of the pursuit of male health and personal improvement to defuse social taboos and normalize ED as a commonly shared functional issue that can be solved.
In other words, the whole stigma around ED is the biggest hurdle ED brands face in marketing and selling products. MGRX is probably the only player on the field directly confronting that fact and navigating around it to the endzone.
The second point is the powerful alignment the company is building in the media channels it chooses to exploit from a marketing standpoint: podcasts that have huge engagement, popularity, and growth in the young male demo.
That’s hardly the only avenue the company is targeting, but that aspect could prove to be an enormous advantage when taken in tandem with its disruptive messaging approach. Make it funny. Make it normal. Make it no big deal. And get in front of men watching media successfully targeting the male demo.
After partnering with Gronk’s Ice Shaker brand, MGRX became a featured sponsor on Barstool Sports and the Only Stans podcast sensation.
The company has also launched its “Make America Hard Again” campaign, which will be augmented by a dedicated web presence and a promise to the campaign into its other marketing efforts to drive a nationwide movement for men’s health and wellness that feeds back into awareness around the company’s products.
No Jumper
Now, just this week, MGRX announced it has been engaged as an exclusive new sponsor by Adam22 and will be featured on a series of No Jumper and Plug Talk episodes beginning in August 2023 (https://www.youtube.com/@NoJumper).
“Adam22 has his finger on the pulse of a demographic that represents an excellent fit for MangoRx, providing a new road to achieving our revenue growth targets by reaching large audiences and promoting our products nationwide,” stated MGRX Co-Founder and CEO, Jacob Cohen. “Our focus right now is on driving powerful sales growth. This partnership holds the potential to create an enormous bump in brand awareness, sales, and market share in the growing men’s health and wellness marketplace, and we look forward to working with Adam and his team beginning next month.”
According to the company’s release, both the No Jumper and Plug Talk podcasts have grown to amass large, engaged audiences. The No Jumper social media universe has amassed nearly 12 million followers across YouTube, Instagram, Tik Tok, Twitter, and Snapchat. Nearly 90% of those followers are male, and 93% are between 18-44 years of age, suggesting a very strong correlation between the MangoRx target market and the large and growing No Jumper audience.
Reportedly, each No Jumper podcast episode averages 100-150k views/downloads, with the No Jumper channel receiving approximately 20 million monthly views. Plug Talk is new, but growing extremely fast, with 30 thousand new subscribers per month and over 50 thousand views per episode.
“We welcome MangoRx on board with open arms,” stated Josh Manheim, Chief Operating Officer of No Jumper. “We look forward to working with Jacob and his team, and we really believe this is a situation where everyone’s interests are very well aligned toward a mutually beneficial outcome. MangoRx is a disruptive new face in its marketplace, and they are once again proving that identity with this partnership.”
Cohen continued, “Past No Jumper episodes have reached into the tens of millions of views, reaching a huge audience that is extremely well-aligned with our target market demographic. The show’s most recent episode hit 10 thousand views within two hours of being posted. This is a cultural phenomenon with enormous traction. Our promotional spots should be highly impactful, with at least a full minute of organic airtime devoted to MangoRx and our products and vision. We couldn’t be more excited about the opportunity this represents.”
All of this follows the company’s recent successful IPO on the Nasdaq, which generated $5,000,000 in gross proceeds earmarked to fund product awareness and operational expansion as the company launches its flagship product line.
